SIRT7 and neoplasm: In addition to the previous pre-clinical xenograft tumor model, we also subcutaneously injected B16F10 melanoma cells with or without SIRT7 deficiency into immune-competent C57B6/L mice to see the effect on tumor growth (Supplementary Fig. S6a, b).